Skip to main content

Advertisement

Table 1 Distribution of patient and tumor characteristics in relation to nuclear VDR expression

From: Vitamin D receptor expression in invasive breast tumors and breast cancer survival

Eligible casesAll
n = 912
 
Tumor in tissue microarray
n (%)
 Yes
718 (78.7)
No
194 (21.3)
Nuclear VDR assessable
n (%)
 Yes
678 (94.4)
No
40 (5.6)
 
Nuclear VDR fraction
n (%)
 Negative
0–10%
125 (18.4)
Positive
11–50%
437 (64.5)
Positive
51–100%
116 (17.1)
   
Factorn (%) or mean (SD)n (%) or mean (SD)n (%) or mean (SD)n (%) or mean (SD)p value*n (%) or mean (SD)n (%) or mean (SD)
Age at baseline56.4 (7.2)55.4 (7.1)56.6 (7.1)55.7 (7.4)0.109**53.9 (7.5)57.6 (7.0)
Age at diagnosis65.4 (8.1)64.1 (7.7)66.0 (7.8)64.8 (8.6)0.026**62.1 (9.1)65.9 (8.3)
Season of diagnosis
 Winter241 (26.4)35 (28.0)116 (26.5)29 (25.0)0.64613 (32.5)48 (24.7)
 Spring221 (24.2)38 (30.4)97 (22.2)27 (23.3)9 (22.5)50 (25.8)
 Summer187 (20.5)19 (15.2)96 (22.0)23 (19.8)6 (15.0)43 (22.2)
 Fall263 (28.8)33 (26.4)128 (29.3)37 (31.9)12 (30.0)53 (27.3)
BMI at baseline
 < 25467 (51.2)60 (48.0)215 (49.2)70 (60.3)0.25324 (60)98 (50.5)
 ≥ 25–30310 (34)45 (36.0)150 (34.3)33 (28.4)11 (27.5)71 (36.6)
 ≥ 30135 (14.8)20 (16.0)72 (16.5)13 (11.2)5 (12.5)25 (12.9)
Tumor size
 1–10 mm229 (25.8)14 (11.2)93 (21.4)33 (28.7)0.00220 (50)69 (39.7)
 11–20 mm409 (46.1)57 (45.6)217 (49.9)51 (44.3)13 (32.5)71 (40.8)
 ≥ 21 mm250 (28.2)54 (43.2)125 (28.7)31 (27.0)6 (15.0)34 (19.5)
 Unknown24021 120
Lymph node status
 Positive262 (31.9)50 (41.0)135 (32.8)36 (32.4)0.2269 (22.5)32 (22.7)
 Negative559 (68.1)72 (59.0)276 (67.2)75 (67.6)27 (67.5)109 (77.3)
 Unknown913265 453
Nottingham grade
 I227 (27.2)7 (5.9)119 (27.7)42 (36.5)< 0.00112 (30.0)47 (34.8)
 II393 (47.0)35 (29.4)219 (50.9)61 (53.0)16 (40.0)62 (45.9)
 III216 (25.8)77 (64.7)92 (21.4)12 (10.4)9 (22.5)26 (19.3)
 Unknown76671 359
Histological type
 Ductal596 (70.9)103 (85.1)290 (67.8)84 (72.4)< 0.00124 (60.0)95 (68.3)
 Lobular166 (19.7)7 (5.8)113 (26.4)20 (17.2)7 (17.5)19 (13.7)
 Other/mixed79 (9.4)11 (9.1)25 (5.8)12 (10.3)6 (15.0)25 (18.0)
 Unknown71490 355
ER status
 Neg (0–10%)84 (10.8)45 (39.5)25 (6.1)4 (3.6)< 0.0013 (7.5)7 (6.0)
 Pos (> 10%)694 (89.2)69 (60.5)382 (93.9)106 (96.4)28 (70.0)109 (94.0)
 Unknown13411306 978
PgR status
 Neg (0–10%)311 (41.7)75 (67.0)135 (34.5)39 (36.8)< 0.00114 (35.0)48 (44.9)
 Pos (> 10%)435 (58.3)37 (33.0)256 (65.5)67 (63.2)16 (40.0)59 (55.1)
 Unknown166134610 1087
HER2
 Neg646 (90.9)102 (91.1)335 (90.3)91 (91)0.95726 (65.0)92 (92.0)
 Pos65 (9.1)10 (8.9)36 (9.7)9 (9.0)2 (5.0)8 (8.0)
 Unknown201136616 1294
Ki67
 Low258 (40.6)16 (15.8)150 (45.9)43 (45.7)< 0.0019 (22.5)40 (44.4)
 Intermediate198 (31.2)28 (27.7)104 (31.8)36 (38.3)5 (12.5)25 (27.8)
 High179 (28.2)57 (56.4)73 (22.3)15 (16.0)9 (22.5)25 (27.8)
 Unknown2772411022 17104
Molecular subtypes
 Luminal A-like350 (55.6)19 (18.6)207 (63.1)62 (66.7)< 0.00111 (27.5)51 (62.2)
 Luminal B-like158 (25.1)33 (32.4)76 (23.2)20 (21.5)8 (20.0)21 (25.6)
 HER2 positive65 (10.3)10 (9.8)36 (11.0)9 (9.7)2 (5.0)8 (9.8)
 Triple negative56 (8.9)40 (39.2)9 (2.7)2 (2.2)3 (7.5)2 (2.4)
 Unknown2832310923 16112
  1. Percentages do not include missing categories
  2. *p values calculated with χ2 test if not otherwise noted. All p values calculated with only valid categories
  3. **Kruskal-Wallis was used to obtain the p value